CLOs on the Move

Intellikine

www.intellikine.com

 
Intellikine is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.intellikine.com
  • 10931 N Torrey Pines Rd Ste 103
    La Jolla, CA USA 92037
  • Phone: 858.768.6500

Executives

Name Title Contact Details

Similar Companies

Chiropractors Buying Group

Chiropractors Buying Group is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Retrophin

Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.

Mountain View Pharmaceuticals

Mountain View Pharmaceuticals is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunovant

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.

Graphite Bio

Graphite Bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. The company`s platform harnesses the natural cellular process of homology directed repair (HDR) and targeted DNA integration to precisely repair genetic defects at their source. Graphite Bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients` lives